Company intelligence / Profile preview

Radella Pharmaceuticals

New York City, New York, USAradellapharma.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Radella’s lead candidate MD-18 is a first-in-class peptide targeting PTP1B via disruption of a non-allosteric protein-protein interaction. In Phase 1a trials, MD-18 demonstrated safety and tolerability with no serious adverse events. Subjects showed improvements in metabolic parameters such as leptin reduction, improved insulin sensitivity, lower ALT, LDL-cholesterol, and total cholesterol compared to placebo. The company is advancing to Phase 1b multiple-dose studies in obese and type 2 diabetes patients[1][5][9].

Therapeutic areas: EndocrinologyCardiovascular
Modalities: Peptides (lead program)Exploring small molecules (preclinical)
Industry: Biotech

Drug pipeline

2 assets

MD-18

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Radella Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Radella Pharmaceuticals.

Explore the full profile